We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
3SBio Inc.'s subsidiary, Sunshine Guojian Pharmaceutical (Shanghai) Co. Ltd. and Verseau Therapeutics, Inc. announced the selection of a monoclonal antibody targeting VSIG4, as a licensed program under their partnership agreement focused on the ...